Background: Data on CA-125 as a predictor of disease progression (PD) in ovarian cancer come predominantly from patients with platinum-sensitive disease receiving chemotherapy alone. We assessed concordance between CA-125-defined and RECIST-defined PD using data from the Gynecologic Cancer InterGroup (GCIG) randomized phase III AURELIA trial in platinum-resistant ovarian cancer (PROC).
introduction
Ovarian cancer is the most lethal gynecologic cancer, resulting in ∼125 000 deaths annually worldwide [1] . Most patients present with advanced disease and will typically be treated with surgery and chemotherapy. Despite such treatment, more than 80% of these patients will experience disease recurrence requiring secondary treatment. Patients whose disease relapses within 6 months after platinum-containing therapy are considered to have platinum-resistant ovarian cancer (PROC), as the likelihood of response to platinum re-exposure diminishes with decreasing interval since last platinum-based chemotherapy [2, 3] .
Ultimately, almost all patients with recurrent disease will develop platinum resistance. Independent of sensitivity to chemotherapy, it is crucial to monitor disease response objectively to determine whether treatment is effective. This is important in a clinical trial setting but also as a decision tool for clinicians determining the utility of continued chemotherapy. Treatment toxicity is also an important consideration when selecting optimal therapy. This applies especially to PROC, where treatment options are very limited and symptom palliation is the main treatment goal.
Radiologic imaging and CA-125 are routinely used to monitor response to systemic treatment in patients with PROC. In clinical trials, radiologic imaging is typically the standard assessment for outcome reporting; it is also required by many regulatory agencies for drug approval. However, disease assessment by imaging is possible only in the subset of patients with measurable disease, and there are concerns regarding exposure to radiation associated with serial imaging, costs, and the considerable degree of intra-and inter-observer variability [4] . Therefore, CA-125 is widely used as an alternative surrogate marker for response and disease progression (PD). CA-125 may provide a better reflection of total tumor burden and has been shown to provide an early indication of impending PD compared with radiological assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) [5] . The Gynecologic Cancer InterGroup (GCIG) recommended a simplified definition of CA-125 criteria as a secondary end point in randomized trials in the first-line setting [6] .
Data supporting the use of CA-125 as an accurate predictor of PD are derived mainly from patients with platinum-sensitive ovarian cancer treated in or followed up after the first-or second-line settings with regimens comprising only cytotoxic agents [7] [8] [9] [10] . It therefore remains uncertain whether CA-125 can be utilized in the platinum-resistant setting. In addition, in patients receiving bevacizumab, there is particular concern about the reliability of CA-125 measurements for assessing PD, as bevacizumab might influence CA-125 levels by altering mucin MUC16 levels [11] . Two single-arm bevacizumab studies demonstrated poor concordance between RECIST-and CA-125-defined PD [11, 12] .
In the present study, we assessed concordance between PD defined by RECIST and by GCIG CA-125 criteria in the GCIG randomized phase III AURELIA trial [13, 14] . To validate our findings, we used data derived from the randomized phase II CARTAXHY trial [15] .
methods study design
We extracted data relating to PD assessed by RECIST and GCIG CA-125 criteria in the AURELIA trial [13] . Briefly, this open-label randomized phase III trial (ClinicalTrials.gov identifier NCT00976911) compared bevacizumab plus chemotherapy versus chemotherapy alone for PROC. Investigators selected single-agent chemotherapy (weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan) before patients were randomized to receive the chosen chemotherapy either alone or combined with bevacizumab 10 mg/kg every 2 weeks (or 15 mg/kg every 3 weeks depending on the chemotherapy schedule). Chemotherapy and bevacizumab were continued until PD by RECIST, unacceptable toxicity, or consent withdrawal. The primary end point was investigator-assessed progression-free survival by RECIST.
study assessments and end points
Tumors were assessed by imaging at baseline and every 8 weeks (or 9 weeks depending on chemotherapy schedule), using the same assessment technique ( preferably computed tomography or magnetic resonance imaging in the case of contrast allergy) throughout the study. Serum CA-125 was assessed at baseline and every 3-4 weeks thereafter.
In this substudy, two definitions of PD were compared: investigatorassessed PD by RECIST and CA-125-defined PD according to GCIG criteria (except that confirmatory CA-125 measurement after PD by CA-125 was not required). RECIST-defined PD was classified further as 'early PD' (≤8 weeks after randomization) or 'late PD' (>8 weeks after randomization). Overall survival (OS) was compared between patients with concordant PD by RECIST and CA-125 versus patients with discordant PD status.
analysis population
This analysis was carried out on the subset of patients with RECIST-defined PD. Detailed information on the criteria for progression in patients in Aurelia who did not progress according to RECIST is given in Figure 1 . Patients without a CA-125 measurement ≤28 days before and ≤21 days after RECIST PD were excluded from the analysis, as were patients with no postbaseline CA-125 measurement.
validation dataset
We validated our findings using data from the CARTAXHY trial [15] . In this open-label randomized phase II trial, 185 patients with PROC were randomized to weekly paclitaxel, weekly paclitaxel plus carboplatin, or weekly paclitaxel plus weekly topotecan for 6-9 cycles or until PD assessed by RECIST and/or CA-125 criteria [6] . We assumed that all patients with measurable disease at baseline were assessed for progression by RECIST; more detailed information on how PD was assessed was unavailable. We applied the same criteria for CA-125 assessments as described above.
statistical analysis
Patients were categorized into two groups according to whether or not they met CA-125 PD criteria. Results are reported as median (range) or as number of patients (%) with corresponding 95% confidence intervals (CIs) as appropriate. Tests for differences in medians between the two groups were carried out by the Wilcoxon rank-sum and by χ 2 test for differences in proportions. OS from the time of RECIST PD was estimated using the KaplanMeier methodology and compared using a stratified log-rank test. Hazard ratios and 95% CIs were estimated using a Cox proportional hazards model. Analyses were carried out in SAS (version 9.3) and STATA (version 14.0).
results patient population
Of the 361 patients randomized in the AURELIA trial, 218 eligible patients (125 in the chemotherapy-alone arm; 93 in the bevacizumab-containing arm) were included in this analysis ( Figure 1 ). Baseline characteristics are provided in supplementary Table S1 , available at Annals of Oncology online. Baseline CA-125 was >35 IU/ml in 197 patients (90%). The median time between RECIST-defined PD and CA-125 assessment was 7 days. The median number of CA-125 measurements before RECIST-defined PD was 4 (range 2-15) in the chemotherapy-alone arm and 6 (range 2-15) in the bevacizumab-containing arm. In 94 patients (43%; 95% CI 36% to 50%), disease had progressed by both RECIST and CA-125. Among patients with CA-125 defined PD preceding RECIST-defined PD (n = 69), the median interval between these PD assessments was 26 (range 1-274) days. The remaining 25 concordant patients had CA-125 PD in the 3-week interval following RECSIT PD. Concordance rates were similar in the chemotherapy-alone and bevacizumab-containing arms (42% versus 45%, respectively; P = 0.6) ( Table 1 ). In the remaining 124 patients with PD by RECIST but not CA-125 criteria, 56 (26%) had increasing CA-125 levels without meeting GCIG criteria for PD [35 (28%) in the chemotherapy-alone arm and 21 (23%) in the bevacizumab-containing arm]. The median increase from nadir in these patients was 42% (range 0.6%-98%) overall [32% (range 2%-98%) for chemotherapy alone and 56% (range 0.6%-98%) for bevacizumab-containing therapy; P = 0.03]. In 42 patients (19%), CA-125 levels decreased, with the lowest value measured at the time of RECIST-defined PD. In 26 (12%) patients, CA-125 levels fluctuated in an oscillating pattern. Baseline characteristics did not differ significantly between patients with PD defined by both RECIST and CA-125 and those with PD defined by RECIST alone (Table 2 ). However, the median time between CA-125 measurement and RECIST-defined PD differed slightly between these subgroups (median 8 versus 5 days, respectively; P = 0.02). There was greater discordance in patients with early PD (within ≤8 weeks after randomization) than in those with later PD (69% versus 53%, respectively, of patients not meeting CA-125 criteria at the time of RECIST PD; P = 0.053).
overall survival
Of the 171 deaths (78% of the analysis population) recorded in the database, 73 (43%) occurred in patients with PD defined by RECIST and CA-125 and 98 (57%) occurred in patients with PD defined by RECIST alone. The median OS from the time of RECIST-defined PD was 10.1 versus 9.0 months, respectively (hazard ratio 1.03, 95% CI 0.76-1.39; log-rank P = 0.87; stratified by randomized treatment) (Figure 2 ).
validation study
In the CARTAXHY trial, 109 of the 165 randomized patients had measurable disease at baseline. Of the 86 patients with PD eligible for our analysis, 40 (46%) also fulfilled GCIG CA-125 criteria for PD, whereas 46 (54%) had no evidence of PD by CA-125. Among the 46 patients with discordant PD assessments, 19 (22%) had increasing CA-125 levels but without meeting GCIG criteria for PD, with a median increase from nadir of 43% (range 1%-93%). In patients with 'early PD', CA-125-assessed PD was less concordant with PD per protocol than in those with later PD (85% versus 49%, respectively, with protocol-defined PD without CA-125-defined PD; P = 0.015).
discussion
This analysis of the AURELIA trial is the first on concordance between RECIST-and CA-125-defined PD in patients with PROC treated with or without bevacizumab. Fewer than half of the patients in either treatment arm had PD according to CA-125 criteria at the time of RECIST-defined PD. Concordance was poor irrespective of bevacizumab treatment. Patients with early PD had poorer concordance between the two PD assessment methods than those with later PD. There was no difference in OS between patients with concordant PD assessments versus those with RECIST-only PD. These findings were validated in an independent dataset (CARTAXHY).
Importantly, this is a post hoc analysis using data from a trial not specifically designed to test the adequacy of the GCIG CA-125 criteria in defining PD. As the primary outcome measure in AURELIA was RECIST-defined PD, CA-125 was not necessarily assessed after PD on study. Furthermore, in patients with available measurements after RECIST PD, crossover to another treatment could potentially have influenced CA-125 measurements. To minimize this potential confounding factor, we limited the analysis population to patients with measurements ≤28 days before and ≤21 days after the date of PD on study. Nevertheless, this approach assumes that RECIST-defined PD is the appropriate gold standard against which CA-125 PD should be compared. Furthermore, concordance was assessed only in the subgroup of patients with RECIST-defined PD on study and fulfilling eligibility criteria for CA-125 assessment. Consequently, our findings may not necessarily apply to all patients with PROC, some of whom will have not have measurable disease assessable by RECIST. Additionally, CA-125 criteria may not be applicable in patients undergoing paracentesis, which can affect CA-125 levels. However, only eight patients in our analysis underwent paracentesis, and there was no significant difference in the median number of procedures between subgroups with concordant versus discordant PD status. In earlier studies, CA-125 elevation was reported to precede RECIST PD by ∼4 months in ∼70% of patients [10, 16] . Based on these early reports, CA-125 monitoring has been widely implemented, supplemented by other non-invasive diagnostics to assess disease status during systematic treatment. However, the clinical value of detecting relapse early has been challenged after a prospective trial showed no benefit from early initiation of systemic therapy based on rising CA-125 in asymptomatic patients [17] . In the North Thames Ovary Trial, CA-125 correctly identified only 46% of patients with clinical PD [7] , raising concerns about false-positive signals that may lead to premature treatment discontinuation. Post hoc analyses of three large trials in platinum-sensitive recurrent ovarian cancer (CALYPSO, OVA-301, Taxol Intergroup Trial) [8, 9, 18] explored whether estimates of treatment effect using CA-125 criteria were consistent with those using standard criteria (RECIST and clinical PD). Although the relative treatment effect in these trials was unaffected, absolute response rates were consistently higher using CA-125 criteria. The proportion of patients with concordant RECIST/clinical PD status and CA-125 criteria was 45%-69%. In CALPYSO and OVA-301, 28% and 35% of patients, respectively, had CA-125 PD before or without RECIST/clinical PD. In patients with subsequent radiological or symptomatic progression, CA-125 PD preceded RECIST PD by a median of >2 months in both trials [8, 17] . In OVA-301, the positive predictive value of CA-125 for PD at 4 months was highly variable (59%-68%), suggesting that even in platinumsensitive disease, CA-125-defined PD is not fully predictive of RECIST-defined PD.
CA-125 has high specificity during follow-up after first-line chemotherapy, but initiating new treatment on the basis of CA-125 alone remains controversial [16, 17] . The GCIG CA-125 criteria for PD were defined with the aim of minimizing the number of patients defined as having PD but who were still deriving benefit from treatment. However, in PROC, in which treatment is often continued until PD, the low sensitivity of CA-125 in detecting PD is concerning. The considerable proportion of patients with falling and fluctuating levels of CA-125 levels at the time of RECIST PD further underlines the potentially clinically relevant inconsistencies between the two measures and questions the value of CA-125 in assessing PD in this population. Furthermore, our analysis of OS also showed that CA-125 levels did not add prognostic information at the time of RECIST-defined PD. The substantial biological heterogeneity within multiple different metastatic deposits in ovarian cancer is well recognized [19] . Clonal selection after multiple treatment lines might explain why in a heavily pre-treated population, CA-125 less reliably predicts changes in disease status.
Nevertheless, imaging also has serious limitations in evaluating PD. In addition to considerable intra-and inter-observer variability [4] , it is uncertain whether a modest increase in the size of a measurable lesion is of clinical significance with regard to clinical PD or lack of symptomatic benefit. As the aim of systemic therapy in PROC is symptom palliation, it may be justified 
